Study of PTC124 in Patients with Nonsense Mutation Dystrophinopathy

• Research type

  Research Study

• Full title

  A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients with Nonsense Mutation Dystrophinopathy

• IRAS ID

  128573

• Contact name

  Kate Bushby

• Contact email

  kate.bushby@ncl.ac.uk

• Sponsor organisation

  PTC Therapeutics, Inc.

• Eudract number

  2012-004527-20

• Clinicaltrials.gov Identifier

  NCT01826487

• REC name

  Wales REC 3

• REC reference

  13/WA/0186

• Date of REC Opinion

  8 Aug 2013

• REC opinion

  Further Information Favourable Opinion